Zurcher Kantonalbank Zurich Cantonalbank lowered its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 16.8% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 6,967 shares of the biotechnology company’s stock after selling 1,411 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in United Therapeutics Corporation were worth $904,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in UTHR. Comerica Bank raised its stake in shares of United Therapeutics Corporation by 1.3% during the 2nd quarter. Comerica Bank now owns 35,249 shares of the biotechnology company’s stock worth $4,635,000 after buying an additional 458 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of United Therapeutics Corporation by 1.8% during the 1st quarter. JPMorgan Chase & Co. now owns 122,497 shares of the biotechnology company’s stock worth $16,583,000 after buying an additional 2,223 shares during the last quarter. Clarity Capital KCPS Ltd. acquired a new position in shares of United Therapeutics Corporation during the 1st quarter worth $230,000. State of Wisconsin Investment Board acquired a new position in shares of United Therapeutics Corporation during the 2nd quarter worth $5,256,000. Finally, Argent Capital Management LLC raised its stake in shares of United Therapeutics Corporation by 2.4% during the 1st quarter. Argent Capital Management LLC now owns 2,530 shares of the biotechnology company’s stock worth $343,000 after buying an additional 60 shares during the last quarter.

Shares of United Therapeutics Corporation (NASDAQ UTHR) opened at 120.75 on Tuesday. The stock has a market cap of $5.25 billion, a PE ratio of 14.00 and a beta of 1.52. The company’s 50-day moving average price is $130.11 and its 200-day moving average price is $130.35. United Therapeutics Corporation has a 52-week low of $110.90 and a 52-week high of $169.89.

United Therapeutics Corporation (NASDAQ:UTHR) last announced its earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) EPS for the quarter, missing the consensus estimate of $3.61 by $4.86. United Therapeutics Corporation had a net margin of 24.18% and a return on equity of 20.96%. The company had revenue of $444.60 million for the quarter, compared to analysts’ expectations of $391.53 million. During the same period in the prior year, the company earned $4.42 earnings per share. The company’s revenue for the quarter was up 7.8% on a year-over-year basis. Analysts expect that United Therapeutics Corporation will post $10.09 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “United Therapeutics Corporation (UTHR) Holdings Reduced by Zurcher Kantonalbank Zurich Cantonalbank” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/09/12/united-therapeutics-corporation-uthr-holdings-reduced-by-zurcher-kantonalbank-zurich-cantonalbank.html.

In other news, CEO Martine A. Rothblatt sold 1,238 shares of the company’s stock in a transaction on Thursday, June 15th. The stock was sold at an average price of $130.20, for a total transaction of $161,187.60. Following the completion of the sale, the chief executive officer now directly owns 1,378 shares of the company’s stock, valued at $179,415.60. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Martine A. Rothblatt sold 1,234 shares of the company’s stock in a transaction on Thursday, June 22nd. The shares were sold at an average price of $132.32, for a total value of $163,282.88. Following the sale, the chief executive officer now directly owns 1,374 shares of the company’s stock, valued at $181,807.68. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 25,178 shares of company stock valued at $3,289,427. 7.80% of the stock is currently owned by company insiders.

UTHR has been the subject of several research reports. ValuEngine downgraded United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 2nd. BidaskClub raised United Therapeutics Corporation from a “sell” rating to a “hold” rating in a research note on Friday, June 16th. Jefferies Group LLC reaffirmed a “sell” rating and set a $105.00 price target on shares of United Therapeutics Corporation in a research note on Thursday, June 8th. UBS AG reaffirmed a “sell” rating and set a $106.00 price target on shares of United Therapeutics Corporation in a research note on Thursday, July 6th. Finally, Zacks Investment Research downgraded United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research note on Thursday, July 13th. Six analysts have rated the stock with a sell rating, seven have issued a hold rating and two have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $134.50.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Stock Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related stocks with our FREE daily email newsletter.